Table 1.
Baseline characteristics of breast cancer (n = 86).
| Feature | n (%)* |
|---|---|
| Receptor status | |
| Estrogen-receptor positive | 72 (83.7) |
| Progesterone-receptor positive | 50 (58.1) |
| HER2 positive | 15 (17.4) |
| Histology | |
| Invasive ductal carcinoma (IDC) | 58 (67.4) |
| Invasive lobular carcinoma (ILC) | 16 (18.6) |
| IDC + ILC | 6 (7.0) |
| Grade 1 | 5 (5.8) |
| Grade 2 | 34 (39.5) |
| Grade 3 | 29 (33.7) |
| Disease extent | |
| Stage IV | 84 (97.7) |
| Liver metastases + | 81 (94.2) |
| 1-3 liver metastases | 1 (1.2) |
| 4-10 liver metastases | 5 (5.8) |
| ≥ 11 liver metastases | 75 (87.2) |
| Prior systemic therapies | |
| Endocrine therapy | 73 (84.9) |
| Tamoxifen | 44 (51.2) |
| Median duration (months) | 35 (16 - 60) |
| Aromatase inhibitor | 60 (69.8) |
| Median duration (months) | 35 (16 - 57) |
| CDK 4/6 inhibitor | 47 (54.6) |
| Anti-HER2 therapy | 16 (18.6) |
| Median duration (months) | 15 (6 - 22) |
| Trastuzumab | 16 (18.6) |
| Pertuzumab | 11 (12.8) |
| TDM1 | 6 (7.0) |
| Chemotherapy | 83 (96.5) |
| Median number of lines | 3 (range 1-10) |
| Anthracycline | 50 (58.1) |
| Taxane | 75 (87.2) |
| Platinum | 6 (7.0) |
| Cyclophosphamide | 52 (60.5) |
*Unless specified in parentheses.